Effects of Nanocrystalline Silver (NPI 32101) in a Rat Model of Ulcerative Colitis
- 12 April 2007
- journal article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 52 (10), 2732-2742
- https://doi.org/10.1007/s10620-006-9738-4
Abstract
Nanocrystalline silver (NPI 32101) has been demonstrated to have antimicrobial and anti-inflammatory properties. The purpose of this study was to assess the effect of NPI 32101 in a rat model of ulcerative colitis and the possible mechanisms of action of the effects observed. NPI 32101, 4 mg/kg intracolonically or 40 mg/kg orally, significantly reduced colonic inflammation compared to the placebo and no-treatment groups. Sulfasalazine (100 mg/kg), either intracolonically or orally, also reduced colonic inflammation. NPI 32101 significantly suppressed the expression of matrix metalloproteinase (MMP)-9, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-12, whereas sulfasalazine suppressed MMP-9, IL-1β, and TNF-α, but not IL-12, compared to placebo. MMP-9 activity was reduced by NPI 32101 and sulfasalazine. NPI 32101 administered intracolonically or orally decreases ulcerative colitis in a rat model and is as effective as sulfasalazine. NPI 32101 treatment suppresses the expression and activity of MMP-9 and the expression of TNF-α, IL-1β, and IL-12, mechanisms by which NPI 32101 may exert its anti-inflammatory effects. NPI 32101 may have therapeutic potential for treatment of ulcerative colitis.Keywords
This publication has 37 references indexed in Scilit:
- Targeted Deletion of Metalloproteinase 9 Attenuates Experimental Colitis in Mice: Central Role of Epithelial-Derived MMPGastroenterology, 2005
- Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitisBritish Journal of Dermatology, 2005
- Anti-inflammatory effect of topical nanocrystalline silver cream on allergic contact dermatitis in a guinea pig modelClinical and Experimental Dermatology, 2004
- A critical approach to new forms of treatment of Crohn's disease and ulcerative colitisAlimentary Pharmacology & Therapeutics, 2002
- Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's diseaseGut, 2002
- Interleukin-12 Antagonists as New Therapeutic Agents in Inflammatory Bowel DiseasePathobiology, 2002
- Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the ratGut, 2001
- Divergent patterns of matrix metalloproteinase activity during wound healing in ileum and colon of rats.Gut, 1996
- Antibodies to interleukin 12 abrogate established experimental colitis in mice.The Journal of Experimental Medicine, 1995
- Modulation of leucocyte adhesion molecules, a T-cell chemotaxin (IL-8) and a regulatory cytokine (TNF-α) in allergic contact dermatitis (rhus dermatitis)British Journal of Dermatology, 1991